M42 and Arcera Life Sciences have entered into a strategic partnership to bolster Abu Dhabi's biopharmaceutical industry and accelerate healthcare innovation, aligning with the Department of Health – Abu Dhabi's goal to establish the emirate as a global life sciences hub. This collaboration aims to cultivate an integrated life sciences ecosystem by focusing on clinical development, advanced therapies for genetic and rare diseases, and leveraging genomics data to study disease prevalence. The partnership will combine M42's healthcare and AI expertise with Arcera's drug development and market access capabilities, concentrating on genomics-based therapeutics, clinical trial acceleration, stem cell research, and AI integration in healthcare, ultimately supporting precision medicine and enhancing patient access to treatments in the region.